IL17A and amyloidosis: Amyloidosis in both liver and spleen was ameliorated in IL-17A-/KCASP1Tg mice (Figure 4a,b), and the expression level of SAA in the liver was decreased compared with 16-week-old KCASP1Tg mice (Supplemental Figure S3b).